If you only remember one thing from the biomarker-testing conversation, make it this: prevention is not about ordering everything. It is about choosing the markers most likely to change how you think, how you monitor yourself, and whether you escalate a conversation. That is why the most useful place to start is the parent guide to biomarker testing UK. This article narrows the question to a practical shortlist.
Why a shortlist matters
Many private panels in the UK are built like supermarket trolleys. There is a bit of everything and no obvious hierarchy. The problem is that preventive value is not evenly distributed. Some biomarkers are strongly tied to major disease pathways and offer good next-step logic. Others are interesting but unlikely to change much on their own.
ApoB belongs near the top
ApoB is one of the strongest blood-based markers for atherogenic particle burden. It often gives a clearer read on cardiovascular risk than total cholesterol and can outperform LDL cholesterol alone in risk discrimination, particularly when triglycerides are raised or the metabolic picture is messy. The ESC and EAS dyslipidaemia guideline is one of the reasons ApoB has moved from specialist conversation to genuinely useful prevention marker.
Read more in ApoB explained for UK patients.
Lp(a) earns its place because it is inherited
Lp(a) is useful because it highlights genetically mediated cardiovascular risk that may not be obvious from routine lipid testing. Many people will never hear about it unless they go looking. That is exactly the sort of blind spot private preventive testing can help close.
Read more in Lp(a) explained for UK patients.
HbA1c is still foundational
HbA1c remains one of the most practical markers for long-term glycaemic exposure. It is not flawless in every biological context, but it is still central to diabetes risk interpretation and metabolic monitoring. If you care about preventive health, it belongs on the list. More here: HbA1c explained for UK patients.
hs-CRP adds inflammatory context
hs-CRP is not a crystal ball, but it is a useful inflammation marker when interpreted alongside the broader picture. In prevention, that often means reading it as part of a pattern, not as an isolated scare signal. More here: hs-CRP explained for UK patients.
What about energy and recovery biomarkers?
For some customers, prevention is not only about future cardiovascular risk. It is also about why they feel under-recovered, metabolically flat, or less resilient than expected. In those cases, the biomarker conversation starts to overlap with cellular-energy testing. See which biomarkers matter for energy for that layer.
How to use the shortlist
A sensible baseline usually starts with high-value markers first, then adds extras if a clear reason exists. If your main concern is cardiovascular risk, ApoB and Lp(a) deserve early attention. If the concern is metabolic drift, HbA1c becomes central. If low-grade inflammation is part of the story, hs-CRP may help. What matters is that the panel reflects your question.
When a shortlist is not enough
A shortlist is a starting framework, not a ban on broader testing. Some people genuinely need more context. A strong family history, unusual symptoms, existing metabolic disease, or the wish to track recovery and performance may justify a wider panel. The important thing is sequence. Start with the markers that have the strongest evidence and clearest next-step value, then widen only when the extra markers answer a real question.
This is also where people go wrong. They buy a broad panel first, then try to reverse-engineer a reason for every number they were given. That creates noise instead of clarity. MeScreen’s opportunity is to make the order feel rational. Start with the markers most likely to affect risk interpretation, then use the result to decide whether deeper investigation is warranted.
Why repeat testing matters
Preventive health is not a single event. It is a trend story. ApoB may improve if diet, weight, medication strategy, or exercise habits change. hs-CRP may settle when inflammatory burden falls. HbA1c may shift meaningfully over a few months if glycaemic control improves. A marker is often most useful when it becomes part of a series rather than a one-off fact.
That is another reason to avoid sprawling panels without a purpose. The more focused the baseline, the easier it is to repeat intelligently and compare like with like. If a test cannot be followed up in a disciplined way, its preventive value drops fast.
Bottom line
The best biomarkers for preventative health are not the most fashionable ones. They are the ones tied to major risk pathways and clear decision-making. Start with the markers that sharpen interpretation, then build from there, not the other way round.
Medically reviewed by Hemal Patel, PhD
Professor of Anesthesiology at UC San Diego School of Medicine, with research interests in mitochondrial biology, caveolin signalling and cellular bioenergetics.
Read Hemal Patel's MeScreen reviewer profile · Verify on UCSD Profiles
References
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020.
- National Institute for Health and Care Excellence. Type 2 diabetes in adults: management, NG28.
- Ridker PM, et al. C-reactive protein and parental history improve cardiovascular risk prediction. Circulation: Cardiovascular Quality and Outcomes. 2008.
Build the full picture
Use the main biomarker testing UK guide to see how these markers fit into a practical prevention baseline, then decide whether a MeScreen assessment is the right next step.